{"name":"Verona Pharma","slug":"verona-pharma","ticker":"VRNA","exchange":"NASDAQ","domain":"vfrpharma.com","description":"","hq":"London, UK / Raleigh, NC","founded":0,"employees":"","ceo":"","sector":"Respiratory / Specialty Pharma","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":280000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Ohtuvayre first approved","drug":"Ohtuvayre","drugSlug":"ensifentrine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Ensifentrine Dose 1","genericName":"Ensifentrine Dose 1","slug":"ensifentrine-dose-1","indication":"Cystic fibrosis","status":"phase_2"},{"name":"RPL554","genericName":"RPL554","slug":"rpl554","indication":"Other","status":"phase_2"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ohtuvayre","genericName":"ENSIFENTRINE","slug":"ensifentrine","indication":"chronic obstructive pulmonary disease (COPD)","status":"marketed"}]}],"pipeline":[{"name":"Ensifentrine Dose 1","genericName":"Ensifentrine Dose 1","slug":"ensifentrine-dose-1","phase":"phase_2","mechanism":"Ensifentrine is a dual inhibitor of the cystic fibrosis transmembrane conductance regulator (CFTR) and the epithelial sodium channel (ENaC).","indications":["Cystic fibrosis"],"catalyst":""},{"name":"Ohtuvayre","genericName":"ENSIFENTRINE","slug":"ensifentrine","phase":"marketed","mechanism":"Ohtuvayre works by blocking an enzyme called phosphodiesterase 3, which helps to increase the levels of a molecule called cyclic AMP in the lungs.","indications":["chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"RPL554","genericName":"RPL554","slug":"rpl554","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}